Paper seeks clarity on biosimilars amid Trump turbulence

The USA’s slow uptake of biosimilars compared to Europe and other markets has not helped to bring down the country’s notoriously high drug prices.

With US President Donald Trump targeting price reductions and Food and Drug Administration (FDA) Commissioner Scott Gottlieb a strong supporter of biosimilar and generic drug development, things might be about to change.

Research group the Institute for Patient Access (IfPA) agrees that this might prove to be the ‘year of biosimilars policy’, although interpreting Mr Trump’s action on medicine costs, which often comprise of threatening or bragging Tweets, can be difficult.